A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 18, 2008

Primary Completion Date

June 21, 2010

Study Completion Date

June 21, 2010

Conditions

Advanced MDSAcute Myeloid Leukemia

Interventions

DRUG

ARRY-520, KSP(Eg5) inhibitor; intravenous

Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.

Trial Locations (2)

Emory University School of Medicine, Winship Cancer Center, Atlanta

University of Texas, M.D. Anderson Cancer Center, Houston